Source：The Insides Company Limited
On：29 April 2024
Organisation：The Insides Company Limited
The Insides Company is pleased to announce the inclusion of The Insides Neo in the Australian Register of Therapeutic Goods (ARTG).
The Insides Neo, a world-first chyme reinfusion solution for pediatric and neonatal patients with severe intestinal failure.
Intestinal failure in neonatal and pediatric patients is most commonly caused by necrotising enterocolitis, a severe condition with mortality rates as high as 50%, making it one of the leading causes of death in preterm infants.
Current management includes the formation of double enterostomy and patients will often present with high-output stoma losses resulting in dehydration and malnutrition.
The Insides Neo is a purpose-built chyme reinfusion solution for reinfusing the intestinal losses in pediatric and neonatal patients with double enterostomies suffering from intestinal failure.
The Insides Neo offers significant benefits compared to the current standard of care by meeting the patient’s nutritional and fluid requirements, reducing surgical and ostomy complications and improving clinical workflow for healthcare professionals by reducing manual labor.
Tina Mason, Quality & Regulatory Manager at The Insides Company said “With the registration of this product in Australia, we are well on our path to achieving our mission to provide universal access to chyme reinfusion therapy. These newborns have now been given an alternative method of treatment, which will deliver essential nutrients that a baby with intestinal failure needs to thrive.”
About The Insides Company
The Insides Company Limited is a leading provider of automated chyme reinfusion solutions for the therapeutic treatment of intestinal failure that has resulted from either a high-output enterocutaneous fistula or enterostomy.
Contacts
The Insides Company LLC
Garth Sutherland, CEO
Email: sales@theinsides.co
.png){kind=small}
